Best Telehealth Clinics in Georgia (2026)

Georgia has one of the more complicated telehealth regulatory environments in the country. The Georgia Composite Medical Board Rule 360-3-.07 governs telehealth practice and contains two restrictions that set the state apart from most others.

First, the Board's rule requires an in-person examination before issuing an initial prescription for controlled substances via telehealth. Second, and more unusually, it requires an in-person exam before prescribing "dangerous drugs," which under Georgia law (O.C.G.A. § 16-13-71) means any prescription drug that is not a controlled substance. This captures GLP-1 medications like semaglutide and tirzepatide, which are not controlled substances but are classified as dangerous drugs. Annual in-person visits from a Georgia-licensed provider are also required. This is far stricter than most states.

The Board's regulatory history on this point has been unstable. The Board voted in December 2023 to rescind COVID-era flexibilities effective January 1, 2024. After public backlash, the effective date was delayed to May 1, 2024. In April 2024, the Board reversed its decision entirely. On January 15, 2025, the Board agreed to accept the federal DEA/HHS extension through the end of 2025. As of 2026, the status depends on further DEA and Board action. This regulatory back-and-forth creates significant compliance uncertainty for telehealth providers.

The insurance parity statute is O.C.G.A. § 33-24-56.4 (Georgia Telehealth Act). HB 307, effective May 4, 2021, amended the act to allow providers and patients to use home settings for telehealth. Georgia is an active member of the IMLC.

One absolute prohibition under Rule 360-3-.07: the Board's telemedicine rule does not authorize prescription of controlled substances for the treatment of pain or chronic pain via telehealth. This is not waived by COVID extensions. Standard TRT is not considered pain treatment and is unaffected.

Georgia has 10.7 million residents and is the eighth-largest state. Despite the large population, provider availability is lower than comparably sized states due to the Board's in-person requirements for both controlled substances and dangerous drugs.

Enhance MD explicitly excludes Georgia from its 11 excluded states. The likely reason is Rule 360-3-.07's in-person requirement for "dangerous drugs," which includes GLP-1 medications. A fully remote telehealth platform cannot comply with the annual in-person visit requirement without local clinic partnerships. Feel30 also excludes Georgia for TRT.

Providers that do serve Georgia for TRT include Maximus ($100/mo, all 50 states), Hone Health ($25/mo entry, all 50 states), and providers listing "Most US states" like BraverX ($129/mo), PeterMD ($99/mo), DudeMeds ($77/mo), and Titan Medical ($99/mo). TRT Nation serves 45 states and does not exclude Georgia. These providers are operating under the federal DEA extension.

GLP-1 providers with all-50-state coverage (Embody, SkinnyRx, DirectMeds, Remedy Meds, GobyMeds, Sesame Care, Shed, MEDVi, Sunlight, Mochi Health) technically serve Georgia, though the in-person dangerous drug requirement creates legal ambiguity for their Georgia operations. Patients should verify that their chosen provider has addressed Georgia's specific requirements.

All HRT, hair loss, and ED providers with national coverage serve Georgia. The in-person requirement for dangerous drugs theoretically applies to all prescription telehealth in the state, though enforcement has been inconsistent.

TRT pricing in Georgia matches national rates: DudeMeds $77/mo ($1,124/year), TRT Nation $99/mo ($1,446/year), PeterMD $99/mo annual ($1,188/year), Maximus $100/mo annual ($1,300/year), BraverX $129/mo ($1,548/year), Defy Medical $200/mo ($2,800/year).

GLP-1 pricing is also national: $99/mo entry (Embody, SkinnyRx, Zealthy), $119/mo (GobyMeds), $179/mo median, $399/mo high end (TrimRx). The practical cost in Georgia may be higher if patients need to arrange in-person visits to comply with state requirements. Some providers may require or recommend an initial in-person consultation, adding travel and copay costs.

Georgia Medicaid does not appear to cover GLP-1s for obesity or weight loss. The state is not among the approximately 13 states that cover weight-loss GLP-1s under Medicaid fee-for-service as of January 2026. GLP-1s for type 2 diabetes (Ozempic, Mounjaro) are covered. Georgia state employee plans cover Wegovy separately from Medicaid.

Georgia does not tax prescription medications. The state sales tax is 4% (plus local), but Rx drugs are exempt. Telehealth consultations are not specifically taxed.

HRT: Midi Health (insurance), PlushCare ($20/mo), Evernow ($35/mo), Alloy ($49/mo). ED: Hims $17/mo to MEDVi $119/mo. Hair loss: Hims $20/mo to Nutrafol $88/mo.

TRT (testosterone replacement therapy)

Georgia Board Rule 360-3-.07 requires an in-person exam before prescribing controlled substances via telehealth. The federal DEA waiver overrides this through 2026. Testosterone (Schedule III) is currently prescribable via telehealth. The Board's chronic pain prohibition does not affect standard TRT. Both compounded and FDA-approved testosterone are available. Georgia providers must hold a Georgia license.

GLP-1 weight loss

This is where Georgia gets unusual. GLP-1 medications are classified as "dangerous drugs" under O.C.G.A. § 16-13-71, and Rule 360-3-.07 requires an in-person exam before prescribing dangerous drugs via telehealth. This is a stricter standard than most states, where GLP-1s face no telehealth restrictions since they are not controlled substances. Enhance MD excludes Georgia for this reason. Whether national providers are technically compliant when prescribing GLP-1s to Georgia patients via telehealth is an open legal question.

HRT (hormone replacement therapy)

HRT medications are also "dangerous drugs" under Georgia law and are technically subject to the in-person requirement. In practice, all major HRT providers serve Georgia. Enforcement has been inconsistent.

Hair loss

Same framework as HRT. Finasteride is a prescription "dangerous drug" subject to Rule 360-3-.07. All major providers serve Georgia regardless.

ED (erectile dysfunction)

Same framework. Sildenafil and tadalafil are prescription "dangerous drugs." All ED providers serve Georgia.

Peptides

Peptide therapy follows federal rules in Georgia. No state-specific peptide restrictions beyond the dangerous drug classification. Maximus (all 50 states) and Defy Medical serve Georgia. MYRNK and Enhance MD may not serve the state.